Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

PHASE3SuspendedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Glioblastoma Multiforme
Interventions
BIOLOGICAL

ICT-107

Autologous dendritic cells pulsed with peptides associated with tumor antigens

BIOLOGICAL

Placebo

Control, autologous monocytes-enriched PBMC.

Trial Locations (65)

4020

Kepler Universitätsklinikum, Neuromed Campus, Linz

5020

University Clinic for Neurology, Salzburg

6020

Medical University Innsbruck, Dept. of Neurology, Innsbruck

10016

Perlmutter Cancer Center, New York

10029

Mount Sinai Medical Center, New York

10032

Columbia University Medical Center, New York

10065

Weil Cornell Medical Center, New York

11042

North Shore University Hospital, Lake Success

14642

University of Rochester Medical Center, Rochester

15232

University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh

17033

Penn State College of Medicine Hershey Medical Center, Hershey

19104

University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University Hospital, Philadelphia

19711

Christiana Care Health Services, Newark

21287

Johns Hopkins University School of Medicine, Baltimore

22903

University of Virginia Health System, Charlottesville

27157

Wake Forest University Health Sciences, Winston-Salem

30309

Piedmont Hospital, Atlanta

30912

Georgia Regents University, Augusta

33484

Delray Medical Center, Boca Raton

33486

Boca Raton Regional Hospital Lynn Cancer Institute, Boca Raton

35294

University of Alabama at Birmingham, Birmingham

37920

University of Tennessee Medical Cancer Institute, Knoxville

40202

Norton Cancer Institute, Louisville

40536

University of Kentucky, Lexington

43210

The Ohio State University Medical Center, Columbus

48109

University of Michigan Health System, Ann Arbor

52242

University of Iowa, Iowa City

55407

John Nasseff Neuroscience Institute, Minneapolis

55416

Metro-Minnesota Community Oncology Research Consortium, Saint Louis Park

60201

NorthShore University Health System, Evanston

60611

Northwestern University, Chicago

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75246

Baylor Health Charles Sammons Cancer Center, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

77030

Houston Methodist Hospital, Houston

University of Texas Health Science Center Memorial Hermann Hospital, Houston

78229

CTRC at UTHSCSA, San Antonio

78705

Texas Oncology, Austin

80045

University of Colorado Denver, Aurora

84112

Huntsman Cancer Institute, Salt Lake City

85013

Dignity Health - St. Joseph's Hospital and Medical Center, Phoenix

87131

New Mexico Cancer Care Alliance, Albuquerque

90027

Southern California Permanente Medical Group, Los Angeles

90033

University of Southern California, Los Angeles

90048

Cedars Sinai Medical Center, Los Angeles

90404

John Wayne Cancer Institute, Santa Monica

91010

City of Hope Cancer Center, Duarte

92093

UCSD Moores Cancer Center, La Jolla

92868

University of California Irvine Chao Family Cancer Center, Orange

94063

Kaiser Permanente, Redwood City

95124

Stanford Cancer Institute, Stanford

95825

Kaiser Permanente, Sacramento

98122

Ivy Center for Advanced Brain Tumor Treatment Swedish Medical Center, Seattle

98195

University of Washington Medical Center, Seattle

06824

Associated Neurologists of Southern Connecticut, Fairfield

06519

Smilow Cancer Hospital, New Haven

02114

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

02215

Harvard Medical School Beth Israel Deaconess Medical Center, Boston

08820

JFK New Jersey Neuroscience Institute, Edison

L8V 5C2

Juravinski Cancer Centre, Hamilton

M5G 2M9

Princess Margaret Hospital, Toronto

H3A2B4

Montreal Neurological Institute & Hospital, Montreal

J1K2R1

CHUS Service de Neurochirurgie, Sherbrooke

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medelis Inc.

INDUSTRY

lead

Precision Life Sciences Group

INDUSTRY